Profile of a patient with tubal peritoneal infertility with unsuccessful attempts of IVF

Tubal-peritoneal infertility ranks first among the reasons for carrying out IVF in the Irkutsk region. The effectiveness of assisted reproductive technologies programs in particular, programs of in vitro fertilization depends on many factors. In addition to the quality of embryos - factor that is almost impossible to influence, the effectiveness of IVF depends on the presence of persistent foci of infection in women with infertility. A retrospective analysis of 83 patients with an established diagnosis of primary infertility, tubal-peritoneal factor, the average age of 35.8 ± 1.5years, the duration of infertility averaged 4.5 ± 1.3 years, the level of Anti-Müllerian hormone (AMG) is not lower than 1 ng/ml (sufficient ovarian reserve), after unsuccessful attempts of application of methods of assisted reproductive technologies (one or more inefficient IVF program). Mostly, patients had normal indices of body mass index. We preformed a retrospective analysis of 83 cases histories of patients of "Mother and child" clinic, Irkutsk, with established diagnosis of primary infertility with tubal-peritoneal factor and composed a clinical profile of a patient. All patients were examined for genital tuberculosis, which was diagnosed in 12 women (14.4 %). Genital tuberculosis as a hidden source of infection has no pathognomonic symptoms and difficult to diagnose, so the presence of indirect signs should alert the obstetrician-gynecologist for early diagnosis of this disease. For early and timely detection of genital tuberculosis in women with reproductive disorders, active implementation of an expanded list of risk factors in the outpatient stage is necessary

THE EPIDEMIOLOGY OF GENITAL TUBERCULOSIS IN REPUBLIC OF BURYATIA DURING 2003-2011

We analyzed official statistical data of 2003—2011 concerning incidence and morbidity of genital tuberculosis in Ulan-Ude. We drown a conclusion that the getting data is not reflect the real problems and true data concerning these pathologies has not been studied yet

FEMALE GENITAL TUBERCULOSIS IN THE MAIN ETHNIC GROUPS IN BURYAT REPUBLIC

The article presents the results of analysis of statistical data and medical cases of women with urogenital tuberculosis, examined at the Republic's clinical TB dispensary in Ulan-Ude (Buryat Respublic) in the 2008-2012. It was shown that in accordance with hospital register the genital TB incidence and the rate of infertility associated with tuberculosis in Buryats and Russian patients are similar

Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial

Aims: To evaluate erythropoietic response rates to oral iron over time in iron-deficient anemic patients with nondialysis- dependent chronic kidney disease (NDCKD). Materials and methods: FIND-CKD was a 1-year, randomized, multicenter trial of iron therapy in patients with ND-CKD, anemia, and iron deficiency, without erythropoiesis- stimulating agent (ESA) therapy. Patients with active infection or C-reactive protein > 20 mg/L were excluded. In this post-hoc analysis, response was defined as 65 1 g/dL increase in hemoglobin (Hb) from baseline, before initiation of alternative anemia therapy (i.e., ESA, transfusion, or intravenous iron). Results: 308 patients received oral iron (200 mg elemental iron/day). Mean (SD) Hb at baseline was 10.4 (0.7) g/dL. At week 4, Hb data were available from 292 patients without alternative anemia therapy: 63/292 (21.6%) showed a response. Among the 229 nonresponders at week 4, 48.8% showed a cumulative response on 651 occasion by week 52 (11.1%, 19.9%, 25.9%, and 28.7% had a response at weeks 8, 12, 24, and 52, respectively), and 27.9% had received alternative iron therapy by week 52. Baseline levels of Hb, ferritin, and transferrin saturation were lower in responders than in nonresponders. Neither concomitant medication nor adherence (as assessed by medication count) was substantially different between early responders and nonresponders. Conclusion: Four weeks after starting oral iron therapy, only 21.6% of anemic patients with ND-CKD and iron deficiency showed an Hb increase of at least 1 g/dL. Among early nonresponders, < 30% responded at any subsequent time point. Earlier consideration of alternative therapy could improve anemia management in this population